Maryland life sciences and biotechnology companies have been at the forefront of the state’s public health response and economic recovery from the COVID-19 pandemic. However, lawmakers are considering policies that weaken the very backbone of Maryland’s robust innovation economy at a time where protecting this industry had never been more critical. Without the necessary policies and protections in place, essential innovation and research, such as COVID-19 clinical trials and cybersecurity development taking place right here in Maryland, could be forced to come to a screeching halt.
Image: Scientists work on the vaccine purification process as they design updates to the Novavax’s COVID-19 shots in the company’s research laboratory on May 24, 2022, in Gaithersburg, Maryland. In July, the U.S. Food and Drug Administration authorized use of Novavax’s more traditional kind of COVID-19 vaccine, which the company hopes can win over unvaccinated people and become a top choice for boosters. (AP Photo/Angie Wang) (Angie Wang/AP)